Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS

Bioanalysis

Volumn 3, Issue 21, 2011, Pages 2459-2480

  Li, Fumin ^a   Fast, Douglas ^a   Michael, Steve ^a  

^a 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOGLOBIN; PROTEIN A;

ACCURACY; ANALYTIC METHOD; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); DRIED BLOOD SPOT; ENZYME DEGRADATION; HUMAN; IMMUNOASSAY; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; WILSON DISEASE;

ANIMALS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TRYPSIN;

EID: 81055125456     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.237     Document Type: Review

References (100)

1. Leader B, Baca QJ, Golan DE.Protein therapeutics: a summary and pharmacological classification.Nat.Rev.Drug Discov.7, 21-39 (2008).
2. Carter PJ.Potent antibody therapeutics by design.Nat.Rev.Immunol.6, 343-357 (2006).
3. Brekke OH, Sandlie I.Therapeutic antibodies for human diseases at the dawn of the twenty-first century.Nat.Rev.Drug Discov.2, 52-62 (2003). (Pubitemid 37361624)
4. Schrama D, Reisfeld RA, Becker JC.Antibody targeted drugs as cancer therapeutics.Nat.Rev.Drug Discov.5, 147-159 (2006).
5. Maggon K.Monoclonal antibody 'gold rush'.Curr.Med.Chem.14, 1978-1987 (2007).
6. Chiou WL.The physiological significance of total body clearance in pharmacokinetic studies.J.Clin.Hosp.Pharm.7, 25-30 (1982).
7. Singh SS.Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.Curr.Drug Metab.7, 165-182 (2006).
8. Damen CW, de Groot ER, Heij M et al.Development and validation of an enzyme-linked immunosorbent assay for the quantitation of trastuzumab in human serum and plasma.Anal.Biochem.391, 114-120 (2009).
9. Junttila TT, Parsons K, Olsson C et al.Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.Cancer 70, 4481-4489 (2010).
10. Wawrzynczak EJ, Denham S, Parnell GD et al.Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse.Mol.Immunol.29, 221-227 (1992).
11. Williams IR, Perry LL.A double determinant sandwich immunoassay for quantitation of serum monoclonal anti-I-A antibody.J.Immunol.Methods 85, 279-294 (1985). (Pubitemid 16174478)
12. Rebello P, Hale G.Pharmacokinetics of CAMPATH-1H: assay development and validation.J.Immunol.Methods 260, 285-302 (2002). (Pubitemid 34132893)
13. Hagman C, Ricke D, Ewert S et al.Absolute quantitation of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry.Anal.Chem.80, 1290-1296 (2008). (Pubitemid 351272367)
14. Walsh G.Biopharmaceuticals: Biochemistry and Biotechnology (2nd Edition).(Ed.) Wiley, London (2003).
15. Kelmsley J.Analyzing protein drugs.Chem.Eng.News 87, 20-23 (2009).
16. Engvall E, Perlmann P.Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G.Immunochem.8, 871-873 (1971).
17. Srebalus Barnes CA, Lim A.Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals.Mass Spectrom.Rev.26, 370-388 (2007). (Pubitemid 46750375)
18. Cheung P.Generation and characterization of antibodies directed against dimodified histones and comments on antibody and epitope recognition.Methods Enzymol.376, 221-234 (2004). (Pubitemid 38200182)
19. Bhogal N.Immunotoxicity and immunogenicity of biopharmaceuticals: design concepts and safety assessment.Curr.Drug Saf.5, 293-307 (2010).
20. Lewis GD, Figari I, Fendly B.et al.Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.Cancer Immunol.Immunother.37, 255-263 (1993). (Pubitemid 23300507)
21. Yates JR, Ruse CI, Nakorchevsky A.Proteomics by mass spectrometry: approaches, advances and applications.Annu.Rev.Biomed.Eng.11, 49-79 (2009).
22. Motoyama A, Yates JR III.Multidimensional LC separations in shotgun proteomics.Anal.Chem.80, 7187-7193 (2008).
23. Aebersold R, Mann M.Mass spectrometry-based proteomics.Nature 422, 198-207 (2003). (Pubitemid 36362757)
24. Elliott MH, Smith DS, Parker CE et al.Current trends in quantitative proteomics.J.Mass Spectrom.44, 1637-1660 (2009).
25. Bantscheff M, Schirle M, Sweetman G et al.Quantitative mass spectrometry in proteomics: a critical review.Anal.Bioanal.Chem.389, 1017-1031 (2007). (Pubitemid 47482251)
26. Ong SE, Mann M.Mass spectrometry-based proteomics turns quantitative.Nat.Chem.Biol.1, 252-262 (2005).
27. Brun V, Masselon C, Garin J et al.Isotope dilution strategies for absolute quantitative proteomics.J.Proteomics.72, 740-749 (2009).
28. Ji QC, Rodila R, Gage EM et al.Mass spectrometric approaches for protein quantitation in drug development.Am.Pharm.Rev.7, 84-89 (2004). (Pubitemid 38868021)
29. Yang Z, Hayes M, Fang X et al.LC-MS/MS approach for quantitation of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup.Anal.Chem.79, 9294-9301 (2007). (Pubitemid 350276306)
30. Heudi O, Barteau S, Zimmer D et al.Towards absolute quantitation of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry.Anal.Chem.80, 4200-4207 (2008). (Pubitemid 351812775)
31. Viswanathan CT, Bansal S, Booth B et al.Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays.Pharm.Res.24, 1962-1973 (2007). (Pubitemid 47389236)
32. US FDA.Guidance for the Industry.Bioanalytical Method Validation.(2001).
33. Li F, Ji QC.Liquid chromatography mass spectrometry bioanalysis of protein therapeutics and biomarkers in biological matrices.In: Mass Spectrometry in Drug Metabolism and Disposition.Lee MS, Zhu M (Eds).John Wiley & Sons, Inc.Hoboken, NJ, USA (2011).
34. Ji QC, Rodila R, Gage EM et al.A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein.Anal.Chem.75, 7008-7014 (2003). (Pubitemid 37523603)
35. Garcia MC, Hogenboom AC, Zappey H et al.Effect of the mobile phase composition on the separation and detection of intact proteins by reversed-phase liquid chromatography-electrospray mass spectrometry.J.Chromatogr.A 957, 187-199 (2002). (Pubitemid 34603262)
36. Kamiie J, Ohtsuki S, Iwase R et al.Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC-MS/MS method combined with novel in silico peptide selection criteria.Pharm.Res.25, 1469-1483 (2008).
37. Wu ST, Ouyang Z, Olah TVet al.A strategy for liquid chromatography/tandem mass spectrometry-based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection.Rapid Commun.Mass Spectrom.25, 281-290 (2011).
38. Becher F, Pruvost A, Clement G et al.Quantitation of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4.Anal.Chem.78, 2306-2313 (2006).
39. De Hoffman E, Charette J, Stroobant V.Mass Spectrometry Principles and Applications (2nd Edition).(Eds).John Wiley & Sons, Inc.NY, USA (2001).
40. Brönstrup M.Absolute quantitation strategies in proteomics based on mass spectrometry.Expert Rev.Proteomics 1, 503-512 (2004). (Pubitemid 43826415)
41. Proc JL, Kuzyk MA, Hardie DB et al.A quantitative study of the effects of chaotropic agents, surfactants and solvents on the digestion efficiency of human plasma proteins by trypsin.J.Proteome Res.9, 5422-5437 (2010).
42. Dubois M, Fenaille F, Clement G et al.Immunopurification and mass spectrometric quantitation of the active form of a chimeric therapeutic antibody in human serum.Anal.Chem.80, 1737-1745 (2008). (Pubitemid 351429580)
43. Li F, Schmerberg CM, Ji QC.Accelerated tryptic digestion of proteins in plasma for absolute quantitation using a protein internal standard by liquid chromatography/tandem mass spectrometry.Rapid Commun.Mass Spectrom.23, 729-732 (2009).
44. de Wilde A, Sadilkova K, Sadilek M et al.Tryptic peptide analysis of ceruloplasmin in dried blood spots using liquid chromatography-tandem mass spectrometry: application to newborn screening.Clin Chem.54, 1961-1968 (2008). (Pubitemid 352774028)
45. Chen EI, Cociorva D, Norris JL et al.Optimization of mass spectrometry-compatible surfactants for shotgun proteomics.J.Proteome Res.6, 2529-2538 (2007). (Pubitemid 47122350)
46. Lill JR, Ingle ES, Liu PS et al.Microwave-assisted proteomics.Mass Spectrom.Rev.26, 657-671 (2007). (Pubitemid 47280716)
47. Pramanik BN, Mirza UA, Ing YH et al.Microwave-enhanced enzyme reaction for protein mapping by mass spectrometry: a new approach to protein digestion in minutes.Protein Sci.11, 2676-2687 (2002). (Pubitemid 35191141)
48. Arsene CG, Ohlendorf R, Burkitt W et al.Protein quantitation by isotope dilution mass spectrometry of proteolytic fragments: cleavage rate and accuracy.Anal.Chem.80, 4154-4160 (2008). (Pubitemid 351812769)
49. Russell WK, Park ZY, Russell DH.Proteolysis in mixed organic-aqueous solvent systems: applications for peptide mass mapping using mass spectrometry.Anal.Chem.73, 2682-2685 (2001). (Pubitemid 32880675)
50. Strader MB, Tabb DL, Hervey WJ et al.Efficient and specific trypsin digestion of microgram to nanogram quantities of proteins in organic-aqueous solvent systems.Anal.Chem.78, 125-134 (2006). (Pubitemid 43050147)
51. Hervey WJ.Strader MB.Hurst GB.Comparison of digestion protocols for microgram quantities of enriched protein samples.J.Proteome Res.6, 3054-3061 (2007). (Pubitemid 47310190)
52. Lin SH, Shaler TA, Becker CH.Quantitation of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap.Anal.Chem.78, 5762-5767 (2006). (Pubitemid 44265037)
53. Kuhn E, Wu J, Karl J et al.Quantitation of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards.Proteomics 4, 1175-1186 (2004). (Pubitemid 38445974)
54. Picotti P, Aebersold R, Domon B.The implications of proteolytic background for shotgun proteomics.Mol.Cell Proteomics 6, 1589-1598 (2007). (Pubitemid 47506169)
55. Liu H, Manuilov AV, Chumsae C et al.Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry.Anal.Biochem.414, 147-153 (2011).
56. Halquist MS, Karnes HT.Quantification of alefacept, an immunosuppressive fusion protein in human plasma using a protein analogue internal standard, trypsin cleaved signature peptides and liquid chromatography tandem mass spectrometry.J.Chromatogr.B 879, 789-798 (2011).
57. Barr JR, Maggio VL, Patterson Jr DG et al.Isotope dilution-mass spectrometric quantitation of specific proteins: model application with apolipoprotein A-I.Clin.Chem.42, 1676-1682 (1996). (Pubitemid 26354748)
58. Kirkpatrick DS, Gerber SA, Gygi SP.The absolute quantitation strategy: a general procedure for the quantitation of proteins and post-translational modifications.Methods 35, 265-273 (2005). (Pubitemid 40255592)
59. Mirzaei H, McBee J, Watts J et al.Comparative evaluation of current peptide production platforms used in absolute quantitation in proteomics.Mol.Cell Proteomics 7, 813-823 (2008). (Pubitemid 351597489)
60. Ji C, Sadagopan N, Zhang Y et al.A universal strategy for development of a method for absolute quantitation of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry.Anal.Chem.81, 9321-9328 (2009).
61. Jemal M, Xia YQ.LC-MS development strategies for quantitative bioanalysis.Curr.Drug Metab.7, 491-502 (2006).
62. Polson C, Sarkar P, Incledon B et al.Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography- tandem mass spectrometry.J.Chromatogr.B 785, 263-275 (2003). (Pubitemid 36126166)
63. Chertov O, Biragyn A, Kwak LW et al.Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry.Proteomics 4, 1195-1203 (2004). (Pubitemid 38445976)
64. Yang Z, Ke J, Hayes M et al.A sensitive and high-throughput LC-MS/MS method for the quantitation of Pegylated-interferon-a2a in human serum using monolithic C18 solid phase extraction for enrichment.J.Chromatogr.877, 1737-1742 (2009).
65. Ji QC, Rodia R, El-Shourbagy TA.A sample preparation process for LC-MS/MS analysis of total protein drug concentrations in monkey plasma samples with antibody.J.Chromatogr.B 847, 133-141 (2007). (Pubitemid 46331015)
66. Anderson NL, Anderson NG.The human plasma proteome: history, character, and diagnostic prospects.Mol.Cell Proteomics 1, 845-867 (2002).
67. Whiteaker JR, Zhao L, Zhang HY et al.Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantitation of serum biomarkers.Anal.Biochem.263, 44-54 (2007). (Pubitemid 46198803)
68. Berna MJ, Zhen Y, Watson DE et al.Strategic use of immunoprecipitation and LC-MS/MS for trace-level protein quantitation: myosin light chain 1, a biomarker of cardiac necrosis.Anal.Chem.79, 4199-4205 (2007). (Pubitemid 46903173)
69. Berna M, Ackermann B.Increased throughput for low-abundance protein biomarker verification by liquid chromatography/tandem mass spectrometry.Anal. Chem.81, 3950-3956 (2009).
70. Lu Q, Zheng X, McIntosh T et al.Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs.Anal.Chem.81, 8715-8723 (2009).
71. Anderson NL, Anderson NG, Haines LR et al.Mass spectrometric quantitation of peptides and proteins using stable-isotope standards and capture by anti-peptide antibodies (SISCAPA).J.Proteome Res.3, 235-244 (2004). (Pubitemid 38500990)
72. Martosella J, Zolotarjova N, Liu H et al.Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins.J.Proteome Res.4, 1522-1537 (2005). (Pubitemid 41464777)
73. Chromy BA, Gonzales AD, Perkins J et al.Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins.J.Proteome Res.3, 1120-1127 (2004). (Pubitemid 40040365)
74. Björhall K, Miliotis T, Davidsson P.Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples.Proteomics 5, 307-317 (2005). (Pubitemid 40189661)
75. Echan LA, Tang HY, Ali-Khan N et al.Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma.Proteomics 5, 3292-3303 (2005). (Pubitemid 41192036)
76. Qian WJ, Jacobs JM, Liu T, Camp DG 2nd, Smith RD.Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications.Mol.Cell Proteomics 5, 1727-1744 (2006). (Pubitemid 44696109)
77. Anderson L, Hunter CL.Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins.Mol.Cell Proteomics 5, 573-588 (2006).
78. Liu T, Qian WJ, Mottaz HM et al.Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry.Mol.Cell Proteomics.5, 2167-2174 (2006). (Pubitemid 44817028)
79. O'Connor D, Mortishire-Smith R, Morrison D et al.Ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry for robust, high-throughput quantitative analysis of an automated metabolic stability assay, with simultaneous determination of metabolic data.Rapid Commun.Mass Spectrom.20, 851-857 (2006). (Pubitemid 43326693)
80. Zhang NY, Fountain ST, Bi HG et al.Quantitation and rapid metabolite identification in drug discovery using API time-of-flight LC-MS.Anal.Chem.72, 800-806 (2000). (Pubitemid 30111521)
81. Naegele E, Fandino AS.Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast liquid chromatography time-of-flight mass spectrometry.J.Chromatogr.A 1156, 196-200 (2007). (Pubitemid 46935732)
82. Bateman KP, Kellmann M, Muenster H et al.Quantitative-qualitative data acquisition using a benchtop Orbitrap mass spectrometer.J.Am.Soc.Mass Spectrom.20, 1441-1450 (2009).
83. Zhang NR, Yu S, Tiller P et al.Quantitation of small-molecules using high-resolution accurate mass spectrometers -α different approach for analysis of biological samples.Rapid Commun.Mass Spectrom.23, 1085-1094 (2009).
84. tm mass analyzer.Bioanalysis 1, 741-754 (2009).
85. Campbell JL, Le Blanc JC.Targeted ion parking for the quantitation of biotherapeutic proteins: concepts and preliminary data.J.Am.Soc.Mass Spectrom.21, 2011-2022 (2010).
86. Barfield M, Spooner N, Lad R et al.Application of dried blood spots combined with HPLC-MS/MS for the quantitation of acetaminophen in toxicokinetic studies.J.Chromatogr.B 870, 32-37 (2008).
87. Rowland M, Emmons GT.Use of dried blood spots in drug development: pharmacokinetic considerations.AAPS J.12, 290-293 (2010).
88. Spooner N, Lad R, Barfield M.Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method.Anal.Chem.81, 1557-1563 (2009).
89. Mei JV, Alexander JR, Adam BW et al.Use of filter paper for the collection and analysis of human whole blood specimens.J.Nutr.131, 1631-1636 (2001).
90. Beaudette P, Bateman KP.Discovery stage pharmacokinetics using dried blood spots.J.Chromatogr.B 809, 153-158 (2004). (Pubitemid 38998433)
91. Wang XL, Wilcken DE, Dudman NP.An indirect sandwich ELISA for LP(a) in serum and dried blood spots.Clin.Chim.Acta 207, 73-86 (1992).
92. Hardelid P, Williams D, Dezateux C et al.Agreement of rubella IgG antibody measured in serum and dried blood spots using two commercial enzyme-linked immunosorbent assays.J.Med.Virol.80, 360-364 (2008).
93. Lutsenko S, Petris MJ.Function and regulation of the mammalian copper-transporting ATPases: insights from biochemical and cell biological approaches.J.Membr.Biol.191, 1-12 (2003). (Pubitemid 37011461)
94. Kroll CA, Ferber MJ, Dawson BD et al.Retrospective determination of ceruloplasmin in newborn screening blood spots of patients with Wilson disease.Mol.Genet.Metab.89, 134-138 (2006). (Pubitemid 44205464)
95. Lee JW, Devanarayan V, Barrett YC et al.Fit-for-purpose method development and validation for successful biomarker measurement.Pharm.Res.23, 312-328 (2006). (Pubitemid 43237862)
96. Ezan E, Bitsch F.Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.Bioanalysis 1, 1375-1388 (2009).
97. Kuang B, King L, Wang HF.Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2, 1125-1140 (2010).
98. Booker HE, Darcey B.Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.Epilepsia 14, 177-184 (1973).
99. Levy RH.Moreland TA.Rationale for monitoring free drug levels.Clin.Pharmacokinetics 9, 1-9 (1984). (Pubitemid 14179495)
100. Ji QC, Rodila R, Morgan SJ et al.Investigation of the immunogenicity of a protein drug using equilibrium dialysis and liquid chromatography-tandem mass spectrometry detection.Anal.Chem.77, 5529-5533 (2005). (Pubitemid 41266046)